Knowing one's genetic makeup can provide informed health decisions towards managing many predisposed diseases. Losing a loved one to cancer or cardiocascular disease such as a heart attack or stroke is a tell tale marker for mapping personal genetics. A patient's genetic hereditary makup can identify health care challenges for clinical providers to manage before they become life threatening.
Bio-Genetics Laboratory offers a full suite of genetic-based tests including cancer (CGX), cardiovascular disease (CardioGx), Alzheimers-Parkinson-dementia (PAD), diabetes, and pharmacogenetics (PGX). Comprehensive and diverse gene panels provide clinical providers with extensive insight into their patient's hereditary risks based on their specific genetic makeup..
Genetic testing is proactive precision medicine. The human genome is the operating manual containing all the instructions that make up the human body. It is unique to each individual. The more one knows about their personal genome and how it works, the more they will understand their own health and can make informed decisions.
We provide a suite of diverse genetic DNA molecular testing that provide insight into specific hereditary risks associated with an individual's genetic makeup.
We provide unparalleled hereditary genetic testing inclusive of comprehensive and easy to read clinical reports along with access to genetic counsleors.
We provide genetic counselor summary reports and consultations for integrating a plan of treatment associated with deleterious genes.
Bio-Genetics Laboratory is a CLIA-certified and CAP Accredited laboratory with a 20-year history of operations. Facilities that operate under CLIA have been found to adhere to established regulations for laboratory testing quality and for reporting of patient-specific results. Clinical Laboratory Improvement Amendments (CLIA) consist of a set of federal standards that are overseen by three federal agencies: the U.S. Food and Drug Administration (FDA), the Centers for Medicare and Medicaid Services (CMS), and the Centers for Disease Control and Prevention (CDC). Any testing performed in the U.S. that yields results used to direct patient care must comply with CLIA standards.
With a CAP-accredited laboratory, you can be assured that they use the most comprehensive, scientifically-endorsed laboratory standards to meet or exceed CLIA requirements. The accrediting agency has evaluated the lab to ensure that its test results are of the highest quality; that assays are developed and implemented to guide accurate decision-making; and to confirm the laboratory is in compliance with CLIA standards, with the agency performing active monitoring to ensure it remains that way over time.
A (CGx) carcinogenetic test identifies specific, inheritable gene mutations that may increase a patient's risk of developing or redeveloping cancer. Gain insight as this test will analyze genes and tumor markers, including BRCA1, BRCA2, ATM, COH1, MLH1, HSH2, MSH6, and PTEN. If a pathogenic variant is identified in your patient, close relatives (children, siblings, and parents) are up to 8 times more likely to also be at increased risk.
Inherited heart conditions are passed on through families and are caused by a change (or mutation) in one or more of a patient's genes. There are many types of inherited heart conditions, including:
Pharmacogenetics test (PGX) focuses on how your patient's body metabolizes drug enzymes and the results will provide you with useful insight as to which medications are more useful, less useful and those that are potentially harmful. Pharmacogenetics is the study of how people respond differently to drug therapy based upon their genetic makeup or genes.
Parkinson’s disease, Alzheimer’s disease, and genetic disorders that cause dementia. Genes play a role in the development of many types of dementia. A patient with a parent or sibling with dementia such as Alzheimer’s disease has on average a higher risk of developing the same condition themselves. Genetic testing can show if a patient has a specific gene that puts them at risk for developing Alzheimer’s.
Patients with a personal and/or family history suggestive of monogenic diabetes and obesity related disorders. These conditions may occur independently or as clinical features of a genetic syndrome. If a pathogenic variant is identified in your patient, close relatives (children, siblings, and parents) are up to 50% more likely to also be at increased risk.
A genetic test that identifies a pathogenic variant is provided via a clinical laboratory report. Bio-Genetics Laboratory provides genetic counseling services for both the doctor and the patient. Incorporating a pro-active risk screening and management protocol into the patient's ongoing plan of treatment can mitigate the health risks before they become life-threatening.
Genetic testing involves the detection of specific alleles, mutations, genotypes or karyotypes that are associated with heritable traits, diseases or predispositions to disease for the individual or their descendants.